Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.
November 2014—BrandTech Scientific announced the availability of inertGrade microplates for the cultivation of nonadherent cell lines, spheroids, and stem cells in a 96-well plate format. The polystyrene plates are treated with a proprietary hydrogel that creates a hydrophobic interface between the surface of the plastic and cellular material to inhibit cell and protein attachment.
November 2014—The Binding Site offers a line of anti-human blood protein antibodies for use by clinical and life science researchers, medical laboratory professionals, and in vitro diagnostic manufacturers.
November 2014—The Food and Drug Administration is allowing the marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury in the 12 hours following administration of the test. Early knowledge that a patient is likely to develop AKI may prompt closer patient monitoring and help prevent permanent kidney damage or death, according to the agency.
November 2014—Dako, an Agilent Technologies company, announced the EU launch of HER2 IQFISH pharmDx automated on Dako Omnis. The assay will enable pathology laboratories to integrate the Dako HER2 IQFISH and IQFISH hybridization buffer into their immunohistochemistry workflow.
November 2014—Abbott has introduced an automated performance-monitoring subscription, mView, for its m2000 molecular diagnostics system. mView is a Web-based service designed to automate data ana-lysis and help laboratories reduce the number of manually generated reports.
November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.
November 2014—GenoLogics has been selected by Illumina as the laboratory information management system provider to support customers of the HiSeq X Ten sequencing system. Under the agreement, the companies will provide support for HiSeq X Ten whole-genome workflows and analysis pipelines, including those to be used inside of Illumina.
November 2014—Biocartis announced the launch of its flagship molecular diagnostics system, Idylla. With Idylla, Biocartis also released its first oncology assay, the Idylla BRAF Mutation Test. Both Idylla and the Idylla BRAF Mutation Test have obtained CE-IVD marking.
October 2014—Neoteryx announced the launch of the Mitra (RUO) Microsampling Device for the collection, transport, storage, and analysis of biological fluids. In seconds, the research-use-only Mitra microsampler consistently collects 10 µL of fluid while eliminating the volumetric blood hematocrit bias typically associated with the dried blood spotting technique.
